免疫腫瘍薬の市場規模、シェア、成長分析、治療タイプ別、疾患タイプ別、流通チャネル別、地域別 - 産業予測、2025～2032年

免疫腫瘍薬の世界市場規模は、2023年に230億2,000万米ドルと評価され、2024年の272億6,000万米ドルから2032年には1,052億6,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは18.4％で成長する見通しです。

免疫腫瘍学（IO）薬は、患者の遺伝子プロファイルや腫瘍の特徴に合わせて治療を行う個別化アプローチにより、がん治療で支持を集めています。この標的戦略は、従来の治療と比較して副作用を最小限に抑え、患者の転帰全体を向上させる。IO薬の主な利点には、生存率の向上、副作用の軽減、長期寛解の可能性などがあります。これは、免疫系を刺激してがん細胞を選択的に識別・破壊し、健康な組織を温存する薬剤の能力によるものです。患者が合併症の減少によるQOLの向上を報告する中、IO療法の持続的な有効性は注目に値するもので、メラノーマや肺がんを含む様々ながん患者において持続的な効果を示しています。この能力は、がんを慢性疾患として効果的に管理し、患者の長期的な福祉を向上させるための変革的な転換を意味します。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制分析
• ケーススタディ分析
• 特許分析

免疫腫瘍薬市場規模：治療タイプ別

• 市場概要
• 免疫チェックポイント阻害剤
• 免疫システム調節剤
• がんワクチン
• 腫瘍溶解性ウイルス
• その他

免疫腫瘍薬市場規模：疾患タイプ別

• 市場概要
• 悪性黒色腫
• 肺がん
• 血液がん
• 腎細胞がん
• 前立腺がん
• 膀胱がん
• その他

免疫腫瘍薬市場規模：流通チャネル別

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局

免疫腫瘍薬市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Coloplast Corp（Denmark）
• Bristol Myers Squibb Company（US）
• Novartis AG（Switzerland）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• Merck & Co., Inc.（US）
• GSK Plc.（UK）
• Eli Lilly and Company（US）
• Fresenius Kabi AG（Germany）
• Pfizer Inc.（US）
• AbbVie Inc.（US）
• Genentech Inc.（US）
• Sanofi（France）
• AstraZeneca（UK）
• Bayer AG（Germany）
• Bluebird Bio, Inc.（US）
• Regeneron Pharmaceuticals, Inc.（US）
• Amgen Inc.（US）
• Johnson & Johnson（US）
• Merck KGaA（Germany）
• Ipsen（France）

結論と推奨事項

Global Immuno-Oncology Drugs Market size was valued at USD 23.02 billion in 2023 and is poised to grow from USD 27.26 billion in 2024 to USD 105.26 billion by 2032, growing at a CAGR of 18.4% during the forecast period (2025-2032).

Immuno-Oncology (IO) drugs are gaining traction in cancer treatment due to their personalized approach, which aligns therapy with patients' genetic profiles and tumor characteristics. This targeted strategy minimizes side effects compared to conventional treatments, enhancing overall patient outcomes. Key advantages of IO drugs include increased survival rates, reduced adverse effects, and potential for long-term remission, driven by the drugs' ability to stimulate the immune system to selectively identify and destroy cancer cells, sparing healthy tissue. As patients report improved quality of life with fewer complications, the enduring effectiveness of IO therapies is noteworthy-showing sustained responses in patients with various cancers, including melanoma and lung cancer. This capability signifies a transformative shift towards managing cancer as a chronic condition effectively and improving long-term patient welfare.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Immuno-Oncology Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Immuno-Oncology Drugs Market Segmental Analysis

Global Immuno-Oncology Drugs Market is segmented by treatment type, disease type, distribution channel and region. Based on treatment type, the market is segmented into immune checkpoint inhibitors, immune system modulators, cancer vaccines, oncolytic virus and others. Based on disease type, the market is segmented into melanoma, lung cancer, blood cancer, renal cell carcinoma, prostate cancer, bladder cancer and others. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Immuno-Oncology Drugs Market

One of the primary catalysts for growth in the Global Immuno-Oncology Drugs market is the approval of these drugs by regulatory agencies. The endorsement from entities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) is crucial, as it validates the safety and efficacy of the drugs, allowing them to be marketed and utilized in clinical settings. These approvals signify a positive outlook for the market, attracting investments from pharmaceutical companies eager to develop new immuno-oncology treatments. As more drugs receive regulatory green lights, healthcare providers gain access to innovative therapies, ultimately improving patient outcomes and fostering further advancements in the field. This dynamic underscores the vital role regulatory approvals play in shaping the immuno-oncology landscape.

Restraints in the Global Immuno-Oncology Drugs Market

The growth of the global immuno-oncology drugs market faces significant challenges primarily due to their high costs. These treatments are often prohibitively expensive, creating financial burdens for both patients and healthcare systems. The exorbitant prices can deter adoption, particularly in regions with limited access to affordable healthcare, adversely impacting market expansion. Moreover, the steep costs may dissuade insurance companies and government healthcare programs from providing coverage, leading to further restrictions on patient access to these essential therapies. Consequently, the high pricing of immuno-oncology drugs stands as a substantial barrier to market growth and patient treatment options.

Market Trends of the Global Immuno-Oncology Drugs Market

The Global Immuno-Oncology (IO) Drugs market is witnessing a significant trend towards the development and integration of biomarkers, enhancing the precision of cancer treatments. Biomarkers enable healthcare professionals to identify patients who are most likely to benefit from immuno-oncology therapies, facilitating personalized treatment approaches. This trend not only improves patient selection and therapeutic outcomes but also minimizes adverse effects by excluding those unlikely to respond. As research advances in identifying new biomarkers, the IO drug market is poised for growth, driving innovations that lead to safer and more effective cancer treatments and ultimately transforming patient care landscapes worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Case Study Analysis
• Patent Analysis

Global Immuno-Oncology Drugs Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Immune Checkpoint Inhibitors
• Immune System Modulators
• Cancer Vaccines
• Oncolytic Virus
• Others

Global Immuno-Oncology Drugs Market Size by Disease Type & CAGR (2025-2032)

• Market Overview
• Melanoma
• Lung Cancer
• Blood Cancer
• Renal Cell Carcinoma
• Prostate Cancer
• Bladder Cancer
• Others

Global Immuno-Oncology Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Immuno-Oncology Drugs Market Size & CAGR (2025-2032)

• North America (Treatment Type, Disease Type, Distribution Channel)
  • US
  • Canada
• Europe (Treatment Type, Disease Type, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Disease Type, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Disease Type, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Disease Type, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Coloplast Corp (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK Plc. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bluebird Bio, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations